Clinical Trials Browser

Withdrawn × INDUSTRY × Hodgkin Disease × Clear all

Hodgkin Disease, Lymphoma, Mucositis

NCT06104878 2024-03-06

A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy Alone

Withdrawn

Lymphoid

Hodgkin Disease

NCT04373083 2021-01-15

Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma

Phase 2 Withdrawn

Lymphoid

Hodgkin Disease

NCT02487459 2020-10-05

Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies

Phase 1 Withdrawn

LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01452334 2012-02-23

Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy

Phase 1 Withdrawn

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Clinical Trials

Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas

A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy Alone

Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma

Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies

Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy